Short answer
Medullary thyroid cancer often triggers germline RET testing because inherited RET pathogenic variants can cause MEN2 and affect relatives. A negative germline RET test makes hereditary MEN2 less likely, but interpretation depends on the exact assay, the specimen, the clinical features, family history, and whether separate tumor testing is being used for treatment decisions. A negative germline result does not mean the tumor has no molecular findings.
What a negative RET result means
| Testing situation | Practical meaning | Why it matters |
|---|---|---|
| Negative germline RET test | Inherited RET-related MEN2 is less likely. | Family-risk counseling may change, but context still matters. |
| MTC with no family history | The cancer may be sporadic. | Sporadic MTC is common, but clinical clues still matter. |
| Negative germline RET with tumor RET finding | The tumor change may be somatic. | Tumor biology and inherited risk are not the same question. |
What it does not mean
MedlinePlus Genetics and GeneReviews both caution that a negative genetic test is not always the end of the story. It does not automatically exclude a hereditary syndrome if the testing method was limited or if the clinical picture still looks like MEN2. It also does not tell you whether the tumor has other molecular changes that may matter for care.
That distinction matters because medullary thyroid cancer can be sporadic or hereditary, and the tumor itself may still be molecularly informative even when germline RET testing is negative. In other words, the family-risk answer and the tumor-biology answer can diverge.
How tumor testing fits in
- Tumor testing asks what changes are inside the cancer itself.
- Germline testing asks whether a change is present in normal cells and could be inherited.
- Paired tumor-normal testing can help separate inherited from somatic findings.
- A negative germline RET result does not rule out tumor-only RET findings or other tumor biomarkers.
When family history changes the next step
Follow-up matters more when a negative RET result does not match a medullary thyroid cancer story, when tumor findings still need a germline answer, or when relatives may still need targeted testing because the family pattern is strong. Genetics counseling helps decide whether the result is truly reassuring or just incomplete.
When specialist review matters
Specialist review matters when the family history or tumor pattern still raises MEN2 concern despite a negative germline result, because a negative test does not always close every question.
How genetic testing is done
Genetic testing is usually done with blood or saliva, and the lab workflow depends on whether the question is a targeted variant, a panel, or confirmation after a clinical finding. Genetics counseling can help clarify whether the next step is a new test, family testing, or a different clinical workup.
Questions to ask
- Was the RET test germline blood or saliva testing, tumor-only testing, or both?
- Did the report cover the relevant RET regions and deletion/duplication analysis?
- Are there MEN2 clues such as pheochromocytoma, hyperparathyroidism, mucosal neuromas, or family history?
- Should tumor testing or paired tumor-normal testing be considered separately?
FAQ
Does a negative RET test rule out MEN2?
It lowers the likelihood of hereditary MEN2, but the exact meaning depends on the test scope, the sample type, and the clinical picture.
Can medullary thyroid cancer still be sporadic if RET is negative?
Yes. MTC can be sporadic, and a negative germline RET result makes inherited RET-related MEN2 less likely.
Do I still need tumor testing if germline RET is negative?
Sometimes yes. Tumor testing can answer a different question, especially about treatment biomarkers or unexpected tumor biology.
Should my relatives be tested if my RET test is negative?
Usually not for a known familial RET variant, but family history and specialist review still matter if the clinical picture suggests inherited risk.
What if the report did not cover all RET regions?
Then the result may be less reassuring, and the exact assay design should be reviewed with the ordering clinician or genetics team.
When should I see a genetics specialist?
When the result affects surgery timing, adrenal screening, family testing, or when there is any ambiguity about tumor versus germline testing.
Related guides: RET tumor testing vs germline testing, RET VUS interpretation, MEN2A vs MEN2B genetic testing, and medullary thyroid cancer genetic counseling questions.